NCT07183852View on ClinicalTrials.gov

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2033

Conditions
Metastatic Uveal MelanomaMetastatic Cutaneous Melanoma
Interventions
DRUG

Autologous Tumor Infiltrating Lymphocytes (TIL)

Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion

DRUG

Melphalan

1 mg/kg, IV

DRUG

Interleukin-2

2 MIU, subcutaneous twice daily for up to 14 days.

All Listed Sponsors
lead

Vastra Gotaland Region

OTHER_GOV